Interview with Igor Krylov, CEO, Pharmstandard
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
Address: Likhachevsky drive 5 «B», Moscow region, Dolgoprudny, 141700,Russia
Tel: +7 (495) 970-0030/32
Web: http://pharmstd.ru/
Pharmstandard is the leader of Russian pharmaceutical industry in R&D and production of the medicinal products.
In 2010, Pharmstandard became №2 among all pharmaceutical companies represented in Russia and market share reached 4.2%.1 Since 2007 Pharmstandard keeps its leading position in commercial segment and remains strong leader among the domestic pharmaceutical company-manufacturers.*1
Pharmstandard became the winner of the national business award ‘Company of the Year 2010’ according to RBC.*2
During the tenth anniversary of «Platinum Ounce 2010», the open competition among professionals of pharma business, Pharmstandard was awarded in the nominations for «The Company of the Year – the Russian pharmaceutical products manufacturer» and «The Company of Decade – the Russian pharmaceutical products manufacturer».
Pharmstandard operates four modern pharmaceutical manufacturing facilities: JSC «Pharmstandard-Leksredstva» in Kursk, JSC «Pharmstandard-UfaVITA» in Ufa, JSC «Pharmstandard-Tomskhimpharm» in Tomsk, PJSC «Pharmstandard-Biolek» in Kharkov (Ukraine) and medical equipment factory JSC «TZMOI» in Tyumen.
The Company has invested approximately RUR 3 billion RUR in modernization and development of production capacities reaching more than 1,35 bln units per year. All the production facilities fully comply with Russian manufacturing standards. Six production lines of JSC «Pharmstandard-Leksredstva» meet EU GMP requirements.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
In 2004-1H2011, we developed and introduced over 55 new pharmaceutical products in close collaboration with the leading scientific centers of Russia. Pharmstandard is the partner of the joint venture biotechnological project «Generium» in order to develop and manufacture innovative biological products within the state program of import substitution.
Pharmstandard became a public company on 4 may 2007 by offering to the public 27.57% of its share capital in the form of GDR on the London Stock Exchange (LSE) and 18.12% of its share capital in the form of ordinary shares on two local stock exchanges (RTS, MICEX). Approximately 54.31%of voting shares of OJSC «Pharmstandard» are held by «Augment Investments Limited».
www.pharmstd.ru
1 Pharmexpert (CMR) 2010 market data.
2 The annual national business award ‘Company of the Year’ is organized by RBK Holdings.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here